Synapse Open Synapse
Biology

Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

BioPharma Dive · · 4 min read

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.

Latest from BioPharma Dive